<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Hepatocellular carcinoma (HCC) is the fifth more common cause of cancer and the third leading cause of cancer deaths worldwide. Despite advances in surgical and non surgical modalities in the treatment of HCC, a number of controversies regarding appropriate diagnostic procedures continue to evolve. A consensus statement from the European Association for the study of Liver Diseases (EASL) has been formulated to help clinicians standardize diagnostic approaches. In nodules greater than 2 cm diameter in size, diagnosis can be made if any 2 imaging studies (ultrasonography, computed tomography, magnetic resonance imaging or hepatic arteriography) show increased vascularity. Alternatively only one imaging study with an Alpha fetoprotein level more than 400ng/mL is diagnostic. Fine needle aspiration biopsy (FNAB) should be performed in cases of indeterminate radiology and in lesions sized between 1 and 2 cm. The aim of this review is to familiarize pathologists in the FNAB diagnosis of HCC in an appropriate and timely fashion.</p></abstract>

Hepatocellular carcinoma (HCC) is the fifth more common cause of cancer and the third leading cause of cancer deaths worldwide. Despite advances in surgical and non surgical modalities in the treatment of HCC, a number of controversies regarding appropriate diagnostic procedures continue to evolve. A consensus statement from the European Association for the study of Liver Diseases (EASL) has been formulated to help clinicians standardize diagnostic approaches. In nodules greater than 2 cm diameter in size, diagnosis can be made if any 2 imaging studies (ultrasonography, computed tomography, magnetic resonance imaging or hepatic arteriography) show increased vascularity. Alternatively only one imaging study with an Alpha fetoprotein level more than 400ng/mL is diagnostic. Fine needle aspiration biopsy (FNAB) should be performed in cases of indeterminate radiology and in lesions sized between 1 and 2 cm. The aim of this review is to familiarize pathologists in the FNAB diagnosis of HCC in an appropriate and timely fashion.

Fine Needle Aspiration Biopsy (FNAB) in the Diagnosis of Hepatocellular Carcinoma: A Review

Department of Cytopathology, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

Department of Radiology and Imaging Sciences, National Institutes of Health (NIH), Clinical Center (CC), Bethesda, MD, USA (2)

Romanian Journal of Internal Medicine

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Hepatocellular carcinoma (HCC) is the fifth more common cause of cancer and the third leading cause of cancer deaths worldwide. Despite advances in surgical...

Fine Needle Aspiration Biopsy (FNAB) in the Diagnosis of Hepatocellular Carcinoma: A Review

Pubblicato online: 14 ott 2015

Pagine: 209 - 217

Ricevuto: 23 apr 2015

DOI: https://doi.org/10.1515/rjim-2015-0028

Parole chiave
Liver, Hepatocellular carcinoma, FNAB, cytology, immunocytochemistry

© 2015 Alexandra Kalogeraki et al., published by De Gruyter Open

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Fine Needle Aspiration Biopsy (FNAB) in the Diagnosis of Hepatocellular Carcinoma: A Review

Pubblicato online: 14 ott 2015

Pagine: 209 - 217

Ricevuto: 23 apr 2015

DOI: https://doi.org/10.1515/rjim-2015-0028

Parole chiaveLiver, Hepatocellular carcinoma, FNAB, cytology, immunocytochemistry

© 2015 Alexandra Kalogeraki et al., published by De Gruyter Open

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Parole chiave
Liver, Hepatocellular carcinoma, FNAB, cytology, immunocytochemistry